Effect of Magnesium and Levocarnitine on Metabolic and Clinical Outcomes in Women With Polycystic Ovarian Syndrome (PCOS)

Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age and is associated with metabolic abnormalities such as insulin resistance, dyslipidemia, and hormonal imbalance, which may lead to infertility and hirsutism. Despite the availability of several pharmacological treatments, many therapies fail to effectively address the underlying metabolic and endocrine dysfunctions of PCOS. Magnesium and L-carnitine are two essential nutrients that may play a synergistic role in improving insulin sensitivity, glucose metabolism, and lipid profile, as

Trial Details

NCT ID
NCT07298564
Phase
NA
Sponsor
Behnood Abbasi
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Magnesium 500 mg
  • Levocarnitine 1000 mg
  • Placebo
  • Placebo Levocarnitine
Locations (sample)
  • Tehran, Tehran Province, Iran|35.69439,51.42151

Key Eligibility Criteria

  • Age between 19 and 65 years.
  • Diagnosis of polycystic ovary syndrome (PCOS) according to the Rotterdam criteria.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →